MyFinsight
Home
About
Contact
telo: the income statement
Download
Download image
Net loss
-$1,102,294
(81.60%↑ Y/Y)
Interest income
$44,182
(186.06%↑ Y/Y)
Total operating costs
$1,146,476
(-80.91%↓ Y/Y)
Research and development
expenses
$759,525
(21.05%↑ Y/Y)
General and
administrative expenses
$386,951
(-92.81%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)